Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Volume
8
Pagination
e185 - e196
Journal
LANCET HIV
Issue
ISSN
2352-3018
Metadata
Show full item recordAuthors
Orkin, C; Oka, S; Philibert, P; Brinson, C; Bassa, A; Gusev, D; Degen, O; Garcia, JG; Morell, EB; Tan, DHSCollections
- Centre for Immunobiology [1114]